RAFFA WEALTH MANAGEMENT, LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

RAFFA WEALTH MANAGEMENT, LLC’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.32K	Buy	21 +2	+11%	+$603	﹤0.01%	532
2026 Q1	$6.29K	Buy	19 +1	+6%	+$340	﹤0.01%	485
2025 Q4	$7.16K	Buy	18 +3	+20%	+$1.33K	﹤0.01%	444
2025 Q3	$6.84K	Buy	15 +2	+15%	+$814	﹤0.01%	428
2025 Q2	$4.24K	Hold	13	–	–	﹤0.01%	534
2025 Q1	$3.51K	Hold	13	–	–	﹤0.01%	496
2024 Q4	$3.06K	Hold	13	–	–	﹤0.01%	556
2024 Q3	$3.58K	Hold	13	–	–	﹤0.01%	491
2024 Q2	$3.16K	Hold	13	–	–	﹤0.01%	621
2024 Q1	$1.94K	Hold	13	–	–	﹤0.01%	721
2023 Q4	$2.49K	Hold	13	–	–	﹤0.01%	550
2023 Q3	$2.3K	Hold	13	–	–	﹤0.01%	543
2023 Q2	$2.47K	Hold	13	–	–	﹤0.01%	549
2023 Q1	$2.6K	Hold	13	–	–	﹤0.01%	537
2022 Q4	$3.09K	Sell	13 -6	-32%	-$1.28K	﹤0.01%	478
2022 Q3	$3.8K	Buy	19 +6	+46%	+$1.14K	﹤0.01%	446
2022 Q2	$1.9K	Hold	13	–	–	﹤0.01%	617
2022 Q1	$2.12K	Hold	13	–	–	﹤0.01%	626
2021 Q4	$2.21K	Hold	13	–	–	﹤0.01%	633
2021 Q3	$2.46K	Hold	13	–	–	﹤0.01%	561
2021 Q2	$2.2K	Sell	13 -14	-52%	-$2.05K	﹤0.01%	598
2021 Q1	$3.75K	Buy	27 +7	+35%	+$1.05K	﹤0.01%	468
2020 Q4	$2.6K	Sell	20 -7	-26%	-$935	﹤0.01%	493
2020 Q3	$3.93K	Buy	27 +2	+8%	+$284	﹤0.01%	368
2020 Q2	$3.7K	Hold	25	–	–	﹤0.01%	365
2020 Q1	$2.72K	Buy	25 +16	+178%	+$1.85K	﹤0.01%	367
2019 Q4	$1.04K	Hold	9	–	–	﹤0.01%	614
2019 Q3	$724	Buy	+9	New	+$712	﹤0.01%	682
2019 Q2	–	Sell	-9	Closed	-$841	–	765
2019 Q1	$841	Hold	9	–	–	﹤0.01%	632
2018 Q4	$656	Hold	9	–	–	﹤0.01%	684
2018 Q3	$788	Hold	9	–	–	﹤0.01%	706
2018 Q2	$886	Hold	9	–	–	﹤0.01%	660
2018 Q1	$1.07K	Buy	+9	New	+$1.16K	﹤0.01%	514
2017 Q4	–	Sell	-1,789	Closed	-$210K	–	257
2017 Q3	$210K	Hold	1,789	–	–	0.09%	83
2017 Q2	$143K	Hold	1,789	–	–	0.06%	90
2017 Q1	$91.7K	Hold	1,789	–	–	0.04%	71
2016 Q4	$67K	Hold	1,789	–	–	0.04%	80
2016 Q3	$121K	Hold	1,789	–	–	0.07%	69
2016 Q2	$99.3K	Hold	1,789	–	–	0.05%	68
2016 Q1	$112K	Hold	1,789	–	–	0.06%	68
2015 Q4	$168K	Hold	1,789	–	–	0.1%	53
2015 Q3	$144K	Hold	1,789	–	–	0.09%	57
2015 Q2	$214K	Hold	1,789	–	–	0.13%	50
2015 Q1	$187K	Hold	1,789	–	–	0.11%	50
2014 Q4	$174K	Hold	1,789	–	–	0.1%	50
2014 Q3	$140K	Hold	1,789	–	–	0.11%	58
2014 Q2	$113K	Hold	1,789	–	–	0.09%	59
2014 Q1	$120K	Hold	1,789	–	–	0.1%	58
2013 Q4	$174K	Buy	+1,789	New	+$107K	0.1%	50

Other funds holding ALNY

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

MIF

Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

RAFFA WEALTH MANAGEMENT, LLC's ALNY Position: Q2 2026 in Review

RAFFA WEALTH MANAGEMENT, LLC increased its Alnylam Pharmaceuticals (ALNY) stake by 11% in Q2 2026, buying an estimated $603 and bringing the position to 21 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in ALNY in Q4 2013 and has held it in 49 quarters since. The position peaked at $214K in Q2 2015. 191 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

RAFFA WEALTH MANAGEMENT, LLC held 21 shares of Alnylam Pharmaceuticals worth $6.32K as of Q2 2026.
RAFFA WEALTH MANAGEMENT, LLC bought 2 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $603.
Alnylam Pharmaceuticals made up ﹤0.01% of RAFFA WEALTH MANAGEMENT, LLC's portfolio in Q2 2026, its #532 holding.
RAFFA WEALTH MANAGEMENT, LLC first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
RAFFA WEALTH MANAGEMENT, LLC's Alnylam Pharmaceuticals position peaked at $214K in Q2 2015.
191 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q2 2026, filed 27 Jul 2026.